Indoline compounds as aldosterone synthase inhibitors

US9550750B2 · kind B2 · utility

Assignees

• Merck Sharp & Dohme LLC · US
• ElexoPharm GmbH · DE

Inventors

• Amjad Ali · Freehold, US
• Michael Man-Chu Lo · Rahway, US
• Edward Metzger · Edison, US
• Lina Yin · Riegelsberg, DE
• Rolf Hartmann · Saarburg, DE
• Qingzhong Hu · Riegelsberg, DE
• Ralf Heim · Riegelsberg, DE
• Christina Zimmer · Völklingen, DE

Key dates

• Filing date: Oct 2, 2013
• Grant date: Jan 24, 2017
• Expiry date: Dec 25, 2033

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07D409/14
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

This invention relates to indo line compounds of the structural formula I, or their pharmaceutically acceptable salts, wherein the variables are defined herein. The inventive compounds selectively inhibit aldosterone synthase. This invention also provides for pharmaceutical compositions comprising the compounds of Formula I or their salts as well as potentially to methods for the treatment amelioration or prevention of conditions that could be treated by inhibiting aldosterone synthase.